SG Americas Securities LLC Makes New $399,000 Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR

SG Americas Securities LLC purchased a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 19,239 shares of the company's stock, valued at approximately $399,000.

• Can Roche Challenge Lilly and Novo in the Weight Loss Market?

A number of other institutional investors have also made changes to their positions in GPCR. Cubist Systematic Strategies LLC boosted its holdings in Structure Therapeutics by 3,326.0% during the first quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock worth $949,000 after buying an additional 53,216 shares during the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $228,000. Exchange Traded Concepts LLC raised its position in shares of Structure Therapeutics by 58.6% in the 2nd quarter. Exchange Traded Concepts LLC now owns 61,732 shares of the company's stock valued at $1,280,000 after acquiring an additional 22,809 shares during the period. Signaturefd LLC boosted its stake in Structure Therapeutics by 6,550.0% during the 2nd quarter. Signaturefd LLC now owns 6,650 shares of the company's stock worth $138,000 after acquiring an additional 6,550 shares during the last quarter. Finally, Trexquant Investment LP grew its holdings in Structure Therapeutics by 127.6% during the first quarter. Trexquant Investment LP now owns 120,340 shares of the company's stock valued at $2,083,000 after purchasing an additional 67,464 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GPCR has been the topic of a number of recent analyst reports. Piper Sandler reissued an "overweight" rating on shares of Structure Therapeutics in a research report on Tuesday, October 28th. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. JMP Securities dropped their price target on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. Lifesci Capital upgraded Structure Therapeutics to a "strong-buy" rating in a research report on Monday, September 8th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Structure Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Structure Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $68.67.

• Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Get Our Latest Stock Analysis on Structure Therapeutics

Structure Therapeutics Trading Up 0.1%

Structure Therapeutics stock opened at $34.22 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 1-year low of $13.22 and a 1-year high of $40.29. The company has a fifty day simple moving average of $30.31 and a 200 day simple moving average of $23.90. The company has a market cap of $1.98 billion, a P/E ratio of -28.05 and a beta of -1.63.

• Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.01). On average, equities research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Stories

• Five stocks we like better than Structure Therapeutics
• What is the Euro STOXX 50 Index?
• Keysight Technologies' Surge: The Market Wakes Up to This AI Play
• What is the S&P/TSX Index?
• Is American Express the Credit Stock For a K-Shaped Economy?
• What is diluted earnings per share (Diluted EPS)?
• Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Structure Therapeutics Right Now?

Before you consider Structure Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Structure Therapeutics wasn't on the list.

While Structure Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here